138 related articles for article (PubMed ID: 23024588)
21. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
22. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
[TBL] [Abstract][Full Text] [Related]
23. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
[TBL] [Abstract][Full Text] [Related]
24. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
25. Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States.
Goldstein M; Fergie J; Krilov LR
Infect Dis Ther; 2021 Mar; 10(Suppl 1):17-26. PubMed ID: 33656649
[TBL] [Abstract][Full Text] [Related]
26. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
Zembles TN; Gaertner KM; Gutzeit MF; Willoughby RE
Am J Health Syst Pharm; 2016 Mar; 73(6):405-8. PubMed ID: 26953285
[TBL] [Abstract][Full Text] [Related]
27. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
Kua KP; Lee SWH
Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
[TBL] [Abstract][Full Text] [Related]
28. Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections.
Jun S; Sebastianski M; Featherstone R; Robinson J
BMJ Open; 2019 Jul; 9(7):e029832. PubMed ID: 31340973
[TBL] [Abstract][Full Text] [Related]
29. Strategies for preventing respiratory syncytial virus.
Forbes M
Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
[TBL] [Abstract][Full Text] [Related]
30. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
31. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
[TBL] [Abstract][Full Text] [Related]
32. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
33. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
[TBL] [Abstract][Full Text] [Related]
34. Adherence to the 2014 American Academy of Pediatrics palivizumab prophylaxis recommendations.
Sierra CM; Park A; Eum E; Garcia G; Lopez M; Daniel SN; Bahjri K; Parbuoni KA
Pediatr Pulmonol; 2021 May; 56(5):1121-1126. PubMed ID: 33314771
[TBL] [Abstract][Full Text] [Related]
35. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
36. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
Warren A; Langley JM; Thomas W; Scott J
Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
[TBL] [Abstract][Full Text] [Related]
37. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
39. Palivizumab for respiratory syncytial virus prophylaxis.
Sandritter T
J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
[TBL] [Abstract][Full Text] [Related]
40. Respiratory Syncytial Virus Bronchiolitis in Children.
Smith DK; Seales S; Budzik C
Am Fam Physician; 2017 Jan; 95(2):94-99. PubMed ID: 28084708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
